Kamada's shares saw a decline following the announcement that the company has halted its Phase 3 study of an inhaled Alpha-1 Antitrypsin (AAT) therapy. The decision to stop the clinical trial is a significant setback for the development of this particular AAT treatment.

KMDA

<p>Kamada 的股票在公司宣佈暫停其吸入型α-1 抗胰蛋白酶（AAT）治療的第三階段研究後出現下跌。停止臨牀試驗的決定對該 AAT 治療的開發是一個重大挫折</p>

由於公司暫停吸入式 AAT 療法的第三階段研究，Kamada 股價下跌